Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, and Chiesi Farmaceutici S.p.A international, research-focused biopharmaceutical group, have announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib. Latham & Watkins LLP represented Gossamer Bio in the transaction with a healthcare and life sciences team led by San Diego partner Steve Chinowsky, and San Diego counsel Darryl Steensma, with London associate Sara Patel. Advice was also provided on corporate matters by San Diego partner Kevin Reyes; on antitrust matters by Washington, D.C. partner Patrick English; on tax matters by San Francisco partner Kirt Switzer, with associate Jake Meninga; and on data privacy matters by San Francisco partner Heather Deixler.~~